<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>A retrospective review was performed of 473 consecutive patients with malignant <z:hpo ids='HP_0002665'>lymphoma</z:hpo> referred to the National <z:e sem="disease" ids="C1306459,C0006826" disease_type="Neoplastic Process" abbrv="">Cancer</z:e> Institute </plain></SENT>
<SENT sid="1" pm="."><plain><z:hpo ids='HP_0000001'>All</z:hpo> patients had their clinical and pathologic material reviewed and where necessary reclassified </plain></SENT>
<SENT sid="2" pm="."><plain>Using a modification of the Rappaport system, 180 (38.1%) patients had a nodular <z:hpo ids='HP_0002665'>lymphoma</z:hpo>, 293 (61.9%) had a diffuse <z:hpo ids='HP_0002665'>lymphoma</z:hpo> </plain></SENT>
<SENT sid="3" pm="."><plain>Nodular <z:hpo ids='HP_0002665'>lymphoma</z:hpo> patients usually presented with <z:hpo ids='HP_0002716'>lymphadenopathy</z:hpo>; diffuse <z:hpo ids='HP_0002665'>lymphoma</z:hpo> patients often presented with extranodal disease, particularly those patients with poorly differentiated lymphocytic, "histiocytic", and Burkitt's <z:hpo ids='HP_0002665'>lymphoma</z:hpo> </plain></SENT>
<SENT sid="4" pm="."><plain>Median age for <z:hpo ids='HP_0000001'>all</z:hpo> patients was 46 years, but was lower for diffuse poorly differentiated lymphocytic, diffuse undifferentiated, and Burkitt's <z:hpo ids='HP_0002665'>lymphoma</z:hpo> patients </plain></SENT>
<SENT sid="5" pm="."><plain>Women were more likely to have a nodular rather than diffuse <z:hpo ids='HP_0002665'>lymphoma</z:hpo> </plain></SENT>
<SENT sid="6" pm="."><plain>P less than 0.05 </plain></SENT>
<SENT sid="7" pm="."><plain>Analyzed by clinical staging, most nodular <z:hpo ids='HP_0002665'>lymphoma</z:hpo> patients had CS III (66.1%) disease, while most diffuse <z:hpo ids='HP_0002665'>lymphoma</z:hpo> patients had either CS III (31.1%) or CS IV (38.9%) disease </plain></SENT>
<SENT sid="8" pm="."><plain>Analyzed by pathologic staging, most nodular <z:hpo ids='HP_0002665'>lymphoma</z:hpo> patients had PS III (34.8%) or PS IV (49.4%) disease, most diffuse <z:hpo ids='HP_0002665'>lymphoma</z:hpo> patients had PS IV (56.3%) disease </plain></SENT>
<SENT sid="9" pm="."><plain>Only 7% of <z:hpo ids='HP_0000001'>all</z:hpo> <z:hpo ids='HP_0002665'>lymphoma</z:hpo> patients had PS I disease, only 14.9% were PS II </plain></SENT>
<SENT sid="10" pm="."><plain>Systemic symptoms were more likely to be found in diffuse <z:hpo ids='HP_0002665'>lymphoma</z:hpo> and/or advanced stage patients </plain></SENT>
</text></document>